论文部分内容阅读
目的观察艾迪注射液联合长春瑞滨(NVB)和顺铂(DDP)(NP方案)治疗晚期非小细胞肺癌(NSCLC)的临床疗效和不良反应。方法 72例晚期NSCLC患者分为联合艾迪注射液化疗组(40例)和单化疗组(30例),观察2组化疗2个周期后有效率(RR)、不良反应情况。结果联合艾迪注射液化疗组有效率高于单化疗组,不良反应低于单化疗组。结论艾迪注射液能提高NP方案的近期疗效,减轻化疗的不良反应,提高生存质量。
Objective To observe the clinical efficacy and side effects of Aidi injection combined with vinorelbine (NVB) and cisplatin (NP) in the treatment of advanced non-small cell lung cancer (NSCLC). Methods Seventy - two patients with advanced NSCLC were divided into two groups: Aidi Injection chemotherapy group (40 cases) and chemotherapy alone group (30 cases). The RR and adverse reactions of the two groups were observed. Results Aidi injection chemotherapy group than the single chemotherapy group, adverse reactions were lower than the single chemotherapy group. Conclusion Aidi injection can improve the short-term efficacy of NP regimen, reduce the adverse reactions of chemotherapy and improve the quality of life.